Interleukin-34 in Stage I and II Periodontitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-01

Study Completion Date

2023-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Interleukin 34 (IL-34) is the second active component of (colony-stimulating factor receptor) CSF-1R. With regards to periodontal disease, It is debatable whether IL-34 is a pro-inflammatory cytokine (as seen in rheumatic arthritis and Sjogren syndrome) or an anti-inflammatory cytokine( as seen in Alzheimer's disease) so further studies could be conducted to better understand whether IL-34 is a proinflammatory or anti-inflammatory cytokine in the pathogenesis of periodontal diseases and to evaluate the change of its levels in Gingival crevicular fluid (GCF) in patients with periodontal disease after non-surgical periodontal therapy (NSPT).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Interleukin-34 Level in Periodontal Disease

NCT05962567

Periodontal Disease Stage 2

UNKNOWN NA

IL-34 Levels in Various Types of Periodontitis

NCT04223869

Chronic Periodontitis Aggressive Periodontitis

COMPLETED NA

IL-39 & IL-35 Gingival Crevicular Fluid Levels in Diabetic Patients With Generalized Periodontitis

NCT05880654

Generalized Periodontal Disease, AVDC Stage 3

COMPLETED NA

Non Surgical Periodontal Treatment Effect on Il-17 and Il-18 in Aggressive Periodontitis

NCT05297084

Aggressive Periodontitis

COMPLETED

Effect of Non Surgical Periodontal Therapy on Inflammatory Markers in Chronic Periodontitis Patients

NCT05295576

Aggressive Periodontitis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Periodontal disease is a multifactorial infection induced by a complex of bacterial species that interact with host tissues and cause destruction of the periodontal structures, including the supporting tissues of the teeth, alveolar bone, and periodontal ligament.

The bacterial biofilm formation initiates gingival inflammation; however, periodontitis initiation and progression depend on dysbiotic ecological changes in the microbiome in response to nutrients from gingival inflammatory and tissue breakdown products that enrich some species and anti-bacterial mechanisms that attempt to contain the microbial challenge within the gingival sulcus area once the inflammation has initiated.

Current evidence supports multifactorial disease influences, such as smoking, diabetes mellitus, obesity, metabolic syndrome, osteoporosis, low dietary calcium and vitamin D and other immunoinflammatory responses that make the dysbiotic microbiome changes more likely for some patients than others and likely influence the severity of disease for such individuals.

During periodontitis, the pathogen triggers the white blood cells of the innate immune system to release proinflammatory mediators such as cytokines that play a vital role in the progression of the inflammation process of periodontitis. In addition, these pathogens can activate the acquired immune system contributing to the release of more cytokines and chemokines that cause permanent bone damage and irreversible periodontal attachment loss.

Cytokines are defined as soluble small proteins (\~5-20 kDa) that bind to specific receptors on certain cells, stimulate some internal cellular changes, and cause multiple genetic and chemical regulations.

There are two different types of inflammatory cytokines: proinflammatory cytokines that are involved in inflammatory reactions including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interleukin-12 (IL-12), tumor necrosis factor-alpha (TNF-α), and anti-inflammatory cytokines that regulate or control the pro-inflammatory cytokine response including interleukin-4 (IL-4), interleukin-1 receptor antagonist (IL-1RA) and interleukin-10 (IL-10).

NSPT aimed at the mechanical removal of bacterial plaque from the tooth surface is considered the "gold standard." This procedure decreases the number of Gram-negative bacteria in favor of Gram-positive bacteria as well as reduces the overall number of microorganisms in periodontal pockets and decreases the amount of proinflammatory cytokines.

Recent methods in oral and periodontal disease diagnostic research are identifying periodontal risk which is quantified by objective measures like biomarkers which are diagnostic tools to measure periodontal disease at the molecular, cellular, tissue, and clinical levels. The biological media for detecting periodontal disease biomarkers include GCF, saliva, serum, subgingival plaque, and tissue biopsies.

The major attraction of GCF as a diagnostic marker is the site-specific nature of the sample which may offer the basis for patient-specific diagnostic tests for periodontal disease. Moreover, the simplicity of its use along with a level of reliability and low cost favors its use over other modalities.

The discovery of new biomarkers will aid in the development of new therapeutic approaches via host modulatory drugs for periodontal disease treatment leading to more individualized, targeted treatments for oral health.

In 2008, Lin identified a secreted protein known as IL-34 with a high functional selectivity represented by stimulating monocyte survival in a CSF-1R-dependent manner. Many studies provided insight into IL-34 biology, but many questions remain unanswered, specifically in terms of its function.

High expression of IL-34 correlates with disease severity in autoimmune diseases (Sjögren's syndrome, SLE, and RA), and inflammatory diseases (liver fibrosis, kidney disease, and inflammatory bowel disease). In contrast, IL-34 plays a protective role in some diseases, such as atopic dermatitis, Alzheimer's disease, breast cancer, and head and neck cancer.

In periodontal disease, some studies such as Guruprasad \& Pradeep in 2018 and Bozkurt Doğan in 2021 suggested that IL-34 is a proinflammatory cytokine in the pathogenesis of periodontal disease while others such as Martinez in 2017 and Lira-Junior in 2021 concluded that IL-34 play a protective role in periodontal disease.

Therefore, Further studies must be carried out to confirm these findings and to better understand the possible role of IL-34 in the pathogenesis of periodontal diseases and to evaluate its levels in GCF in patients with periodontal disease after NSPT

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cytokine Storm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Nonsurgical periodontal debridement was performed on patients using an ultrasonic scaler and universal curettes (2R - 2L and 4R- 4L). Oral Hygiene measures were instructed following treatment and follow-up after 3 months.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stage I grade B periodontitis patients

Nonsurgical periodontal debridement was performed on patients using an ultrasonic scaler and universal curettes (2R - 2L and 4R- 4L). Oral Hygiene measures were instructed following treatment and maintenance visits were given to them.

Group Type ACTIVE_COMPARATOR

Non-Surgical periodontal therapy

Intervention Type PROCEDURE

Supra and Subgingival debridement for all patients except periodontally healthy individuals

Stage II grade B periodontitis patients

Nonsurgical periodontal debridement was performed on patients using an ultrasonic scaler and universal curettes (2R - 2L and 4R- 4L). Oral Hygiene measures were instructed following treatment and maintenance visits were given to them.

Group Type ACTIVE_COMPARATOR

Non-Surgical periodontal therapy

Intervention Type PROCEDURE

Supra and Subgingival debridement for all patients except periodontally healthy individuals

Periodontally healthy individuals

No intervention

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-Surgical periodontal therapy

Supra and Subgingival debridement for all patients except periodontally healthy individuals

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with stage I and II grade B Periodontitis in addition to periodontally healthy individuals.
* Both genders aged from 20-50 years
* Minimum 20 natural teeth excluding third molars.
* Good compliance with the plaque control instructions following initial therapy.
* Availability for follow-up and maintenance program.

Exclusion Criteria

* Smokers.
* Pregnant and lactating females.
* Systemic diseases that could affect the outcome of the therapy (According to the Cornell Medical Index-Health Questionnaire).
* Patients taking antibiotics, anti-inflammatory drugs, and immunosuppressive therapy during the preceding 6 months before the start of the trial and during the study.
* Patients who have undergone any periodontal therapy in the last 6 months.
* Vulnerable groups of patients' e.g. (handicapped patients).

Minimum Eligible Age

20 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes